keyword
https://read.qxmd.com/read/38621307/primary-intracranial-peripheral-primitive-neuroectodermal-tumor-lessons-from-an-exceptionally-rare-neoplasm-illustrative-case
#1
JOURNAL ARTICLE
Jhon E Bocanegra-Becerra, Luis Felipe Novoa-Ramírez, Alan Jesús Latorre-Zúñiga, Norka Tacas-Gil, Rolando Rojas-Apaza
BACKGROUND: The primary intracranial peripheral primitive neuroectodermal tumor (pPNET) is a lesion subtype within the Ewing sarcoma family of tumors. pPNETs are extremely uncommon pathologies, accounting for 0.03% of intracranial tumors and 1% to 2% of Ewing sarcoma cases. Given its histological aspect similar to other highly proliferative malignant neuroectodermal neoplasms, pPNET merits extensive workup for accurate diagnosis and treatment. OBSERVATIONS: A 36-year-old male presented to the emergency department with a 1-year history of headaches in the right frontoparietal area, generalized tonic-clonic seizures, and a history of the resection of a tumor labeled as a meningioma 5 years before admission...
April 15, 2024: J Neurosurg Case Lessons
https://read.qxmd.com/read/38621246/infectious-diseases-what-you-may-have-missed-in-2023
#2
JOURNAL ARTICLE
Amena Alhammadi, Rasha Alshawaf, Swati Chavda, Sonya Ramondino, Mindy Schuster
In 2023, published research on COVID-19 remains prominent. The aim of this article is to highlight important developments in infectious disease evidence unrelated to COVID-19 that were published in 2023. The literature was screened for sound new evidence relevant to internal medicine specialists and subspecialists whose focus of practice is not infectious diseases. The highlighted publications relate to various organisms and patient populations. One article provides insight into the updated guidelines for the diagnosis and management of infective endocarditis...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38621244/oncology-what-you-may-have-missed-in-2023
#3
JOURNAL ARTICLE
Courtney H Coschi, Lorin Dodbiba, DuPont Guerry
Advances in oncology treatment methods have improved outcomes and quality of life for patients with cancer. However, care of these patients can be complex, and the contribution of physicians from different specialties is crucial. This article highlights important publications from 2023 on topics across a wide spectrum relating to the management of oncology patients. The literature was screened for significant new evidence that is relevant to internal medicine specialists and subspecialists whose focus is not oncology...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38621243/critical-care-what-you-may-have-missed-in-2023
#4
JOURNAL ARTICLE
Henry Ajzenberg, Mansor Abdalaziz N Binhashr, Mark Keith Hewitt, Michael Unger
Critical care medicine is a specialty that brings together a truly wide spectrum of patient populations, disease states, and treatment methods. This article highlights 10 important pieces of research from 2023 (and 1 from 2022) in critical care. The literature was screened for new evidence relevant to internal medicine physicians and hospitalists whose focus of practice is not critical care but who may be taking care of seriously ill patients. The articles highlight the diverse spectrum of pathology and interplay of various specialties that go into critical care...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38621242/cardiology-what-you-may-have-missed-in-2023
#5
JOURNAL ARTICLE
Abdulrahman Alfraih, Achieng Tago, Michael Lacombe, William G Kussmaul
Cardiology and all its subspecialties continue to push the envelope in developing new treatment strategies for a wide variety of diseases. After screening more than 1300 articles, we highlight a selection of important cardiology articles published in 2023. Starting with prevention, we note articles that look at the effect of semaglutide in patients with obesity as well as a first-in-class drug, bempedoic acid, on cardiovascular outcomes. We have also examined new evidence comparing conservative management with invasive management of frail, older patients with non-ST-segment elevation myocardial infarction (NSTEMI)...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38621241/gastroenterology-hepatology-what-you-may-have-missed-in-2023
#6
JOURNAL ARTICLE
Sama Anvari, Kayla Dadgar, Ciarán Galts, Michael Bretthauer
This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38621173/scaffold-based-poly-vinylidene-fluoride-and-its-copolymers-materials-fabrication-methods-applications-and-perspectives
#7
REVIEW
Wenbin Sun, Chuang Gao, Huazhen Liu, Yi Zhang, Zilong Guo, Chunxiang Lu, Hao Qiao, Zhiqiang Yang, Aoxiang Jin, Jianan Chen, Qiqi Dai, Yuanyuan Liu
Tissue engineering involves implanting grafts into damaged tissue sites to guide and stimulate the formation of new tissue, which is an important strategy in the field of tissue defect treatment. Scaffolds prepared in vitro meet this requirement and are able to provide a biochemical microenvironment for cell growth, adhesion, and tissue formation. Scaffolds made of piezoelectric materials can apply electrical stimulation to the tissue without an external power source, speeding up the tissue repair process. Among piezoelectric polymers, poly(vinylidene fluoride) (PVDF) and its copolymers have the largest piezoelectric coefficients and are widely used in biomedical fields, including implanted sensors, drug delivery, and tissue repair...
April 15, 2024: ACS Biomaterials Science & Engineering
https://read.qxmd.com/read/38620134/rational-design-of-a-novel-class-of-human-clpp-agonists-through-a-ring-opening-strategy-with-enhanced-antileukemia-activity
#8
JOURNAL ARTICLE
Xinrong Xiang, Zhengyi Dai, Baozhu Luo, Ninglin Zhao, Song Liu, Jing Sui, Jiasheng Huang, Yuanzheng Zhou, Jinlong Gu, Jiangnan Zhang, Tao Yang, Rui Bao, Youfu Luo
The activation of Homo sapiens Casein lysing protease P (HsClpP) by a chemical or genetic strategy has been proved to be a new potential therapy in acute myeloid leukemia (AML). However, limited efficacy has been achieved with classic agonist imipridone ONC201 . Here, a novel class of HsClpP agonists is designed and synthesized using a ring-opening strategy based on the lead compound 1 reported in our previous study. Among these novel scaffold agonists, compound 7k exhibited remarkably enhanced proteolytic activity of HsClpP (EC50 = 0...
April 15, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38620111/detection-of-various-lung-diseases-including-covid-19-using-extreme-learning-machine-algorithm-based-on-the-features-extracted-from-a-lightweight-cnn-architecture
#9
JOURNAL ARTICLE
Md Nahiduzzaman, Md Omaer Faruq Goni, Md Robiul Islam, Abu Sayeed, Md Shamim Anower, Mominul Ahsan, Julfikar Haider, Marcin Kowalski
Around the world, several lung diseases such as pneumonia, cardiomegaly, and tuberculosis (TB) contribute to severe illness, hospitalization or even death, particularly for elderly and medically vulnerable patients. In the last few decades, several new types of lung-related diseases have taken the lives of millions of people, and COVID-19 has taken almost 6.27 million lives. To fight against lung diseases, timely and correct diagnosis with appropriate treatment is crucial in the current COVID-19 pandemic. In this study, an intelligent recognition system for seven lung diseases has been proposed based on machine learning (ML) techniques to aid the medical experts...
June 26, 2023: Biocybernetics and Biomedical Engineering
https://read.qxmd.com/read/38620059/blue-light-activated-water-soluble-sn-iv-porphyrins-for-antibacterial-photodynamic-therapy-apdt-against-drug-resistant-bacterial-pathogens
#10
JOURNAL ARTICLE
T Nagarajan, M P Gayathri, John Mack, Tebello Nyokong, Sutharsan Govindarajan, Balaji Babu
Antimicrobial resistance has emerged as a global threat to the treatment of infectious diseases. Antibacterial photodynamic therapy (aPDT) is a promising alternative approach and is highly suitable for the treatment of cutaneous bacterial infections through topical applications. aPDT relies on light-responsive compounds called photosensitizer (PS) dyes, which generate reactive oxygen species (ROS) when induced by light, thereby killing bacterial cells. Despite several previous studies in this area, the molecular details of targeting and cell death mediated by PS dyes are poorly understood...
April 15, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38619832/serious-bleeding-in-patients-with-atrial-fibrillation-using-diltiazem-with-apixaban-or-rivaroxaban
#11
JOURNAL ARTICLE
Wayne A Ray, Cecilia P Chung, C Michael Stein, Walter Smalley, Eli Zimmerman, William D Dupont, Adriana M Hung, James R Daugherty, Alyson Dickson, Katherine T Murray
IMPORTANCE: Diltiazem, a commonly prescribed ventricular rate-control medication for patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly causing overanticoagulation. OBJECTIVE: To compare serious bleeding risk for new users of apixaban or rivaroxaban with atrial fibrillation treated with diltiazem or metoprolol. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included Medicare beneficiaries aged 65 years or older with atrial fibrillation who initiated apixaban or rivaroxaban use and also began treatment with diltiazem or metoprolol between January 1, 2012, and November 29, 2020...
April 15, 2024: JAMA
https://read.qxmd.com/read/38619822/sodium-glucose-cotransporter-2-inhibitors-vs-sulfonylureas-for-gout-prevention-among-patients-with-type-2-diabetes-receiving-metformin
#12
JOURNAL ARTICLE
Natalie McCormick, Chio Yokose, Na Lu, Deborah J Wexler, J Antonio Aviña-Zubieta, Mary A De Vera, Rozalina G McCoy, Hyon K Choi
IMPORTANCE: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are a revolutionary treatment for type 2 diabetes (T2D) with cardiovascular, kidney, and serum urate-lowering benefits. OBJECTIVE: To compare risk of incident gout and rate of recurrent flares between patients with T2D initiating SGLT2i vs sulfonylurea, most common second-line glucose-lowering therapy, when added to metformin monotherapy. DESIGN, SETTING, AND PARTICIPANTS: This sequential, propensity score-matched, new-user comparative effectiveness study using target trial emulation framework included adults with T2D receiving metformin monotherapy in a Canadian general population database from January 1, 2014, to June 30, 2022...
April 15, 2024: JAMA Internal Medicine
https://read.qxmd.com/read/38619807/hepatitis-c-virus-core-antigen-a-diagnostic-and-treatment%C3%A2-monitoring-marker-of-hepatitis-c-virus-in-indian-population
#13
JOURNAL ARTICLE
Jaya Garg, Prashant Verma, Mridu Singh, Anupam Das, Anurag Pathak, Jyotsna Agarwal
BACKGROUND: The diagnosis and treatment monitoring of hepatitis C is quite challenging. The screening test, i.e. antibody assay, is unable to detect acute cases, while the gold standard hepatitis C virus (HCV) reverse transcriptase polymerase chain reaction (RTPCR) assay is not feasible in resource-limited countries such as India due to high cost and infrastructure requirement. European Association for the Study of the Liver and World Health Organization have approved a new marker, i...
April 15, 2024: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://read.qxmd.com/read/38619802/cost-utility-analysis-of-vericiguat-in-heart-failure-with-reduced-ejection-fraction-after-worsening-heart-failure-events-in-china
#14
JOURNAL ARTICLE
Penglei Chen, Yixiang Wang, Xin Liu, Jiaqi Yu, Xuwei Zheng
OBJECTIVE: Vericiguat is a new medication to demonstrate clinical efficacy in heart failure with reduced ejection fraction (HFrEF) after worsening heart failure (WHF) events, but its cost-utility was unknown. We aimed to assess the cost-utility of combining the application of vericiguat with standard treatment in HFrEF patients who had WHF events. METHODS: A multistate Markov model was implemented to mimic the economic results of HFrEF patients who had WHF events in China after receiving vericiguat or placebo...
April 15, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38619788/comparative-study-on-anti-vegf-in-wet-age-related-macular-degeneration-in-the-setting-based-on-lean-methodology-from-the-bari-intravitreal-injection-registry-bivir
#15
JOURNAL ARTICLE
Maria Oliva Grassi, Pasquale Viggiano, Enrico Borrelli, Giacomo Boscia, Teresa Molfetta, Maria Giovanna Malerba, Maria D'Addario, Ermete Giancipoli, Giovanni Alessio, Francesco Boscia
INTRODUCTION: Optimizing treatment protocols for wet age-related macular degeneration (wAMD) is an ongoing challenge, as it involves a delicate balance between achieving therapeutic efficacy and minimizing invasive procedures' frequency. This study aimed to apply the Lean methodology and evaluate the effectiveness of this new setting on intravitreal therapy for wAMD, employing different anti-vascular endothelial growth factors (VEGF) drugs (bevacizumab, brolucizumab, aflibercept, ranibizumab), drawing data from the Bari Intravitreal Injections Registry (BIVIR)...
April 15, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38619775/risk-of-cardiovascular-events-in-schizophrenic-patients-treated-with-paliperidone-palmitate-once-monthly-injection-pp1m-a-population-based-retrospective-cohort-study-in-taiwan
#16
JOURNAL ARTICLE
Shih-Pei Shen, Li Yan, Tao Wu, Min-Wei Huang, Kuan-Chih Huang, Hong Qiu, Yongjing Zhang, Chao-Hsiun Tang
BACKGROUND: Schizophrenia is one of the leading causes of disability. Paliperidone palmitate once-monthly injection (PP1M) was developed to provide consistent drug delivery and improve medication adherence for maintenance treatment. It is well known that patients with schizophrenia have higher cardiovascular risks, however little is known about the cardiovascular risks of patients with schizophrenia treated with PP1M in Asia. OBJECTIVE: This study aimed to estimate the incidence of cardiovascular events after initiating PP1M treatment and evaluate the cardiovascular risk associations compared with oral second-generation antipsychotics (SGAs)...
April 15, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38619744/imaging-findings-and-toxicological-mechanisms-of-nervous-system-injury-caused-by-diquat
#17
JOURNAL ARTICLE
Yanguang Ren, Feng Guo, Lin Wang
Diquat (DQ) is a nonselective bipyridine herbicide with a structure resembling paraquat (PQ). In recent years, the utilization of DQ as a substitute for PQ has grown, leading to an increase in DQ poisoning cases. While the toxicity mechanism of DQ remains unclear, it is primarily attributed to the intracellular generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) through the process of reduction oxidation. This results in oxidative stress, leading to a cascade of clinical symptoms...
April 15, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38619719/real-world-effectiveness-and-safety-of-ramucirumab-as-a-second-line-treatment-for-patients-with-unresectable-advanced-or-metastatic-gastric-gastroesophageal-junction-adenocarcinoma-in-japan-and-south-korea-a-systematic-literature-review
#18
REVIEW
Xiaotian Zhang, Li Zhou, Chan Zhou, Lin Shen
INTRODUCTION: Gastric cancer has the highest incidence and mortality in Eastern Asia. The efficacy and safety of ramucirumab (RAM) monotherapy or in combination with paclitaxel (PTX) for patients with unresectable advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEA) have been established in clinical trials. To assess the effectiveness and safety of RAM or RAM-based therapy as a second-line treatment in real-world clinical practice in Eastern Asia and to pave the way for future research, a systematic literature review (SLR) was conducted...
April 15, 2024: Advances in Therapy
https://read.qxmd.com/read/38619711/drug-coated-balloon-in-acute-coronary-syndromes-ready-for-the-prime-time
#19
REVIEW
Simone Fezzi, Sara Malakouti, Jegan Sivalingam, Jacinthe Khater, Flavio Ribichini, Bernardo Cortese
PURPOSE OF REVIEW: Acute coronary syndromes (ACS) are a major global health concern. Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES) has been endorsed as safe and effective in the management of culprit and non-culprit lesions of ACS. However, permanent metallic implants may have drawbacks, including the need for prolonged dual antiplatelet therapy (DAPT) and the risk of long-term stent-related complications. An alternative approach using drug-coated balloons (DCBs) is gaining growing interest, having the potential of delivering therapy directly to vulnerable plaques, avoiding the need for permanent metallic implants, and potentially allowing for better long-term medical treatment...
April 15, 2024: Current Cardiology Reports
https://read.qxmd.com/read/38619682/novel-pikfyve-tubulin-dual-target-inhibitor-as-a-promising-therapeutic-strategy-for-b-cell-acute-lymphoblastic-leukemia
#20
JOURNAL ARTICLE
Zhen Lu, Qian Lai, Zhi-Feng Li, Meng-Ya Zhong, Yue-Long Jiang, Li-Ying Feng, Jie Zha, Jing-Wei Yao, Yin Li, Xian-Ming Deng, Bing Xu
OBJECTIVE: In B-cell acute lymphoblastic leukemia (B-ALL), current intensive chemotherapies for adult patients fail to achieve durable responses in more than 50% of cases, underscoring the urgent need for new therapeutic regimens for this patient population. The present study aimed to determine whether HZX-02-059, a novel dual-target inhibitor targeting both phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) and tubulin, is lethal to B-ALL cells and is a potential therapeutic for B-ALL patients...
April 15, 2024: Current Medical Science
keyword
keyword
55933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.